Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension

Inclusion Criteria: * Both genders aged 18 years or older; * Currently on dual antihypertensive therapy for at least 8 weeks, and non responders to that treatment, defined as measurements of SBP ≥ 140 mmHg and ≤180 mmHg and/or DBP≥90mmHg and ≤110 mmHg, assessed at the screening visit and randomization visit (both conditions are in accordance with the Brazilian Hypertension Guideline - 2020); * Able to understand and consent to their participation in this clinical trial, manifested by signing the Informed Consent Form; Exclusion Criteria: * Any significant clinical condition that, in the investigator's opinion, may interfere with participant safety; * Any laboratory test finding that, in the investigator's opinion, may interfere with participant safety; * Suspected or diagnosed with COVID 19; * History of hypersensitivity to components of drugs used during the trial or to drugs derived from sulfonamides; * Pregnant or breastfeeding women; * Women in a reproductive age who do not agree to use contraceptive methods; * Male participants who do not agree to use contraceptive methods; * Participation in clinical trial protocols in the last 12 (twelve) months, unless the investigator judges that there may be a direct benefit to the participant; * Participant who has some kind of relationship up to the second degree or bond with collaborators or employees of the Sponsor and the Research site; * Estimated glomerular filtration rate (eGFR) less than 45 ml/min /1.73m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation) or end-stage renal disease; * Severe liver dysfunction; * Cardiogenic shock or reduced ejection fraction heart failure with a left ventricular ejection fraction less than or equal to 50%; * Symptomatic congestive heart failure class II, III or IV, according to the New York Heart Association and/or participants with a history of infarction, unstable angina or cerebrovascular accident in the last 6 months prior to the beginning of the study; * Clinically relevant ventricular cardiac arrhythmias; * Obstructive coronary artery disease planning percutaneous or surgical intervention; * Dementia syndrome; * History of alcohol or illicit drug addiction in the six months prior to the date of signature of the Informed Consent Form; * Obstructive biliary disorders; * Refractory hypokalemia and/or conditions involving marked potassium loss, hyperkalemia (\>5,5 mmol/L), and/or hyponatremia; * History of symptomatic hyperuricemia; * History of secondary hypertension; * History of cancer, without documentation of remission/cure;